CoChat

Dickkopf-1: a suitable target for the management of myeloma bone disease

Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Christoulas, Dimitrios, Migkou, Magdalini, Iakovaki, Marina, Gkotzamanidou, Maria, Terpos, Evangelos · 2009 · Expert Opinion on Therapeutic Targets
Cited by 68

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Bone disease remains a major problem in the management of patients with multiple myeloma (MM) and is characterized by the presence of lytic lesions due to increased osteoclastic activity and reduced osteoblast function. Wingless-type and integrase 1 (Wnt)/beta-catenin signaling is a central pathway for bone development and homeostasis. Dickkopf-1 (Dkk-1) is a soluble inhibitor of Wnt, which disrupts osteoblast differentiation and action. Dkk-1 is produced by myeloma cells and overexpressed in myeloma microenvironment of patients with extensive bone disease. In addition to its direct inhibitory effect of Dkk-1 on osteoblasts, Dkk-1 disrupts the Wnt3a-regulated osteoprotegerin and receptor activator of NF-kappaB ligand (RANKL) expression in osteoblasts and thus it indirectly enhances osteoclast function in MM. Dkk-1 serum and bone marrow plasma levels are increased in MM patients and correlated with advanced International Staging System stage and presence of osteolytic lesions. Preclinical studies in mouse myeloma models showed that targeting Dkk-1 with neutralizing anti-Dkk-1 antibodies resulted in increased numbers of osteoblasts, reduced numbers of multinucleated osteoclasts and increased bone volume. The bone anabolic effect of anti-Dkk-1 may also be associated with reduced myeloma burden. These data show that Dkk-1 has a pivotal role in bone health and disease and is a novel target for the management of myeloma patients with lytic bone disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728220903025770

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 68

Metadata

Authors
Gavriatopoulou, M., Dimopoulos, M.-A., Christoulas, D., Migkou, M., Iakovaki, M., Gkotzamanidou, M., & Terpos, E.
Venue
Expert Opinion on Therapeutic Targets
Published
2009-06-17
Volume
13
Issue
7
Pages
839-848
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2057120263
Cited by
68
References
15
FWCI
4.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dickkopf-1: a suitable target for the management of myeloma bone disease. https://app.cochat.ai/papers/10.1517/14728220903025770
The paper
Gavriatopoulou, M., Dimopoulos, M.-A., Christoulas, D., Migkou, M., Iakovaki, M., Gkotzamanidou, M., & Terpos, E. (2009). Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728220903025770

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.